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Abstract
Albright’s hereditary osteodystrophy (AHO) is a rare
inherited disease characterized by skeletal abnormali-
ties, short stature, and, in some cases, resistance to para-
thyroid hormone, resulting in pseudohypoparathyroid-
ism (PHP). Heterozygous inactivating mutations of the
GNAS1 gene are responsible for reduced activity of the
alpha subunit of the Gs protein (GS·), a protein that
mediates hormone signal transduction across cell mem-
branes. Gs· is also known to have oncogenic potentials,
leading to the development of human pituitary tumors
and Leydig cell tumors. Here, we report the 1st case, a
3.5-year-old girl, with classic AHO phenotype and PHP
type 1A associated with a cerebellar pilocytic astrocyto-
ma. Coincidence or genetic relationships of both dis-
eases are discussed according to molecular findings and
current literature.
Copyright © 2001 S. Karger AG, Basel
Introduction
Albright’s hereditary osteodystrophy (AHO; MIM No.
103580) is a rare autosomal dominantly inherited syn-
drome characterized by short stature, obesity, round face,
brachymetaphalangism, subcutaneous ossification, and
variable mental retardation [1]. Pseudohypoparathyroid-
ims type IA (PHP IA) in AHO patients results from resis-
tance of target organs to parathyroid hormone (PTH)
caused by a deficient alpha subunit of the Gs protein (GS·)
[2, 3], a guanosine triphosphate binding protein that cou-
ples hormone receptors to the stimulation of adenylate
cyclase as a second messenger [4]. In patients with PHP
IA, the activity of the GS· protein is reduced to 50% [5]
due to heterozygous inactivating mutations in the gene
encoding the GS· subunit (GNAS1) [6]. In contrast, acti-
vating mutations of GNAS1 have been found in McCune-
Albright syndrome [7], in growth hormone producing
pituitary adenoma, and ovarian and testicular Leydig cell
tumors, suggesting that it functions as a protooncogene [8,
9]. GNAS1 is located at 20q13.2–13.3 [3] and consists of
13 exons encoding a 394 amino acid protein [6]. Here we
describe the 1st case of AHO associated with a cerebellar
pilocytic astrocytoma in a young child.
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Fig. 2. a T1-weighted MRI with gadolinium shows a well-demar-
cated vermian lesion within the fourth ventricle. b Postoperative T1-
weighted MRI with gadolinium confirming complete tumor re-
moval.
Fig. 1. Pedigree of the family with Albright’s hereditary osteodystro-
phy and PHP IA showing that the disease was maternally inherited
affecting two out of four siblings. The index patient II:2 developed a
cerebellar astrocytoma.
Case Report
A 3.5-year-old Caucasian girl was admitted to the Department of
Pediatrics after a grand mal seizure. Physical examination revealed
typical features of AHO, including short stocky stature (weight
13.1 kg, height 83 cm, height SDS –4.5), round face, brachydactyly,
cutaneous calcification, and mental retardation. Neurological exami-
nation was without focal deficits. Laboratory evaluation revealed
hypocalcemia (1.24 mmol/l; normal range 2.08–2.60 mmol/l), hyper-
phosphatemia (3.91 mmol/l; normal range 0.87–1.45 mmol/l), and
elevated PTH level (991 pg/ml; normal range: 11–54 pg/ml), consis-
tent with the diagnosis of PHP. Serum thyroid-stimulating hormone
was elevated (11.3 mU/l; normal !4 mU/l); T3 and T4 were within
normal limits, providing biochemical evidence of resistance to thy-
roid-stimulating hormone. The urinary cyclic adenosine monophos-
phate excretion was in the lower normal range. Adrenocorticotropin,
growth hormone, prolactin, cortisol, luteinizing hormone, insulin-
like growth factor 1, and insulin-like growth factor binding protein 3
were within normal limits. Follicle-stimulating hormone was ele-
vated (8.8 U/l; normal range !0.5–3.2 U/l). A 1-year-old brother of
our index patient also exhibited AHO with PHP IA. Their mother
had AHO with pseudopseudohypoparathyroidism. The father and
two sisters demonstrated no abnormal findings (fig. 1).
Radiological examinations of the girl revealed cutaneous calcifi-
cation at the medial malleolus of the left foot, frontal hyperostosis,
coxa valga, brachydactyly of hands and feet, caudal narrowing of the
lumbar spinal canal, and osteoporotic signs on chest X-ray. Cerebral
MRI demonstrated a well-circumscribed lesion with a diameter of
3 cm in the fourth ventricle (fig. 2a). On CT scan, there was evidence
of intracranial calcifications of the basal ganglia. The intracerebellar
mass was explored through a medial suboccipital approach to the
fourth ventricle. The tumor could easily be separated from the adja-
cent brain and was completely removed (fig. 2b). Postoperatively, the
patient was without neurological deficits and showed an unremarka-
ble course. Histopathological examination revealed a pilocytic astro-
cytoma (WHO grade I) with frequent microcysts and complete
absence of anaplasia.
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Fig. 3. All 3 AHO-affected family members carried a heterozygous C-to-T transition 30 bp upstream from the 5)
splice site of intron 7 in the germline (a). In contrast, all 3 non-affected family members as well as 103 control
individuals demonstrated the wild-type sequence only (b).
Methods
DNA Extraction, PCR, and Sequence Analysis
For molecular analysis, genomic DNA extracted from peripheral
blood leukocytes of all 6 family members including the index patient
was screened for germline mutations of the GNAS1 gene. In addition,
DNA was extracted from snap-frozen tissue of the cerebellar astrocy-
toma collected at the time of surgery using microdissection tech-
niques and was analyzed for somatic mutations of the GNAS1 gene.
In brief, genomic DNA was amplified from exon 2 to exon 13 of the
GNAS1 gene, including intron/exon boundaries using cyanine-
labelled primers described previously [10, 11]. Each PCR mix con-
sisted of 60 ng of DNA, 0.1 ÌM of each primer, 1 ! PCR buffer, 2.0
mM MgCl2, 200 ÌM dNTPs, and 0.75 IU of Taq polymerase (Perkin
Elmer) in a total volume of 25 Ìl. PCR reactions were performed in a
GeneAmp 9700 thermocycler (Perkin-Elmer) at 94°C for 30 s, 58°C
for 30 s, and 72°C for 1 min for a total of 35 cycles with an initial
denaturation step (95 °C for 5 min) and a final extension step (72°C
for 7 min). PCR-amplified products were separated on agarose gel,
excised, purified with MicroSpin S-200 HR columns (Amersham
Pharmacia Biotech) and subjected to cycle-sequencing reactions for
20 cycles using the Thermo Sequenase dye primer cycle sequencing
kit (Amersham Pharmacia Biotech). After a denaturation step (94°C
for 5 min) cycle sequencing products were resolved on an automated
laser fluorescence sequencer (ALF Express; Amersham Pharmacia
Biotech) using 6.5% Long Ranger gels at 40 W (1,000 V, 40 mA).
Control Individuals and Polymorphism Analysis
Using cyanine-labelled primers (exons 7–10: upstream 5)-GCG
CTG TGA ACA CCC CAC GTG TCT-3); downstream 5)-CGC
AGG GGG TGG GCG GTC ACT CCA-3)) [11], a 711-bp PCR
product was amplified. A two-allele polymorphism (C-to-T transi-
tion) was detected among the family members 30 bp upstream from
the 3)-splice site of intron 7 by nucleotide sequence analysis (fig. 3).
The wild-type allele (A1) contains two HinF I restriction sites, one of
which is eliminated by the C-to-T transition in the mutant allele (A2).
Restriction endonuclease digestion of the 711-bp PCR product from
individuals who were homozygous for the A1 allele generated two
cyanine-labelled fragments with a length of 121 and 452 bp, respec-
tively. In individuals who were heterozygous for the alleles A1A2,
three cyanine-labelled fragments of 121, 259, and 452 bp were gener-
ated. The allele frequency was estimated from the analysis of the
polymorphic site in 103 unrelated Caucasians. After HINF I diges-
tion according to the manufacturer’s protocol (New England Bio-
Labs), DNA fragments were separated on 6.5% Long Ranger poly-
acrylamide gels on an automated laser fluoresence sequencer (ALF;
Amersham Pharmacia, Biotech).
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RNA Extraction and RT-PCR
mRNA was extracted and purified from blood and tumor tissue
cells by the use of a QuickPrep Micro mRNA purification kit (Am-
ersham Pharmacia Biotech) and stored at –80 °C. cDNA was gener-
ated with RT-PCR using random hexamer primers supplied by the
first-strand cDNA synthesis kit (Amersham Pharmacia Biotech)
according to the manufacturer’s protocol. The coding region between
exon 6 and exon 10 was then amplified from 1.5 Ìl of the cDNA
reaction mixture using a sense primer (5)-TCT GTG GGA GGA
TGA AGG AGT G-3)) and an antisense primer (5)-AGG CGG TTG
GTC TGG TTG TC-3)). The PCR was performed in a final volume
of 22 Ìl containing 0.18 ÌM of each primer and 0.8 IU of Taq poly-
merase. The PCR consisted of 35 cycles of 1 min at 94°C, 1 min at
58°C, and 1 min at 72°C with an initial denaturation step of 5 min
at 94°C and a final elongation step of 7 min at 72°C. The amplified
GNAS1 cDNA fragments were subjected to electrophoresis on an 1%
agarose gel and visualized after ethidium bromide staining. Glyceral-
dehyde-3-phosphate dehydrogenase specific primers (sense 5)-ACA
GTC CAT GCC ATC ACT GCC-3); antisense 5)-GCC TGC TTC
ACC ACC TTC TTG-3)) were employed as positive controls under
the same PCR conditions mentioned above.
GS· Bioactivity
The activity of GS· protein from erythrocyte membranes of the
patients was analyzed in vitro according to the method of Levine et
al. [3]. After solubilization and activation of the GS· protein, the gen-
eration of cyclic adenosine monophosphate was measured by ra-
dioimmunoassay using adenylyl cyclase from turkey red cell mem-
branes in the presence of adenosine triphosphate. Results were
obtained in triplicate and were expressed as percentage of the mean
of healthy controls.
Results
GS· Bioactivity
In all 3 AHO patients of the family (index patient,
mother, brother) the GS· bioactivity was reduced to
approximately 50%.
Mutation Analysis
No mutations were found in genomic DNA within the
coding region of exon 2 to exon 13, including intron/exon
boundaries, except an intronic C-to-T transition 30 bp
from the splice donor site of exon 7 (In7sds+30). This
polymorphism was found in all AHO patients but not in
healthy family members (fig. 3). The allelic frequency of
the polymorphism was analyzed with HinF I restriction
digestion in genomic DNA of 103 anonymous healthy
blood donors, who served as control individuals. In all
206 control alleles the wild-type sequence was detected,
thus excluding a common polymorphism.
To evaluate a possible effect on the transcriptional lev-
el, RT-PCR was performed between exon 6 and exon 10
which did not reveal any alternatively spliced variants.
Two known polymorphisms within exon 5 and exon 13 of
GNAS1 revealed homozygous allele patterns for all 3
affected family members and could, therefore, not be used
to analyze for possible exclusive transcription of the wild-
type sequence.
As expected, the germline polymorphism in intron 7
was also detected in the genomic DNA of the cerebellar
astrocytoma. No other mutations were found in tumor
DNA, neither at the two well-known oncogenic mutations
sites (Arg 201 and Gln 227) nor within the complete cod-
ing region between exon 2 and exon 13 of GNAS1.
Discussion
AHO is a rare inherited syndrome characterized by a
specific phenotype with skeletal abnormalities and, in
some cases, PHP. PHP is caused by resistance to PTH
resulting from deficiency of the alpha chain of the stimu-
latory guanine nucleotide binding protein (GS·). Hetero-
zygous inactivating mutations of the GNAS1 gene, encod-
ing for the GS· protein, have been associated with para-
thyroid and thyroid hormone resistance in AHO patients
[5, 12, 13]. In a series of 8 patients with AHO and PHP
IA, GNAS1 mutations were found in half of the cases
[14].
GNAS1 is imprinted in a promoter-specific fashion,
and PHP IA is virtually always inherited maternally [15],
as it was in our case. The patient exhibited the classic phe-
notype of AHO combined with PHP IA, including a defi-
cient GS· bioactivity of 50%. Accordingly, a heterozy-
gously inactivated GNAS1 gene has to be expected at the
genomic level. However, no mutations were found in the
coding region of GNAS1 despite a reduction of the GS·
enzyme activity. Nevertheless, an intronic polymorphism
was detected which was strictly related to the disease car-
rier and was not found in nonaffected family members or
in 103 control individuals. At the transcriptional level,
there was no evidence for abnormal splice variants caused
by this polymorphism.
Although a decreased translation efficiency cannot be
excluded, it seems to be more likely that the intronic poly-
morphism is linked with a nondetected mechanism of
gene inactivation such as promoter or enhancer altera-
tions or mutations within exon 1 [15]. A potential associa-
tion of the polymorphism and AHO remains to be evalu-
ated by determining the allele frequency in other AHO
families. We could not exclude that our results included
an incidental finding.
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GNAS1 is also known to have an oncogenic potential.
Two oncogenic mutation sites (Arg 201 and Gln 227) of
the GNAS1 gene have been shown to cause autonomous
cyclic adenosine monophosphate production in 43% of
growth hormone secreting human pituitary tumors [9,
16]. Cyclic adenosine monophosphate is an intracellular
second messenger and has the ability to stimulate cell
growth [17, 18]. It has been shown that autonomous activ-
ity of the Gs protein, that is able to transmit proliferative
signals of extracellular hormones, promotes tumor growth
by inhibiting the guanosine triphosphatase of the guano-
sine triphosphate binding subunit of the GS· protein [19].
The oncogene was termed gsp and was also found to be
mutated in 4 out of 6 (66.6%) ovarian and testicular Ley-
dig cell tumors [8]. In corticotroph adenomas of the pitu-
itary, gsp mutations were found less frequently (2 out of
32 patients) [20].
Previously, a 53-year-old woman with PHP and a cere-
bellar pilocytic astrocytoma was described [21]. No mo-
lecular studies were performed in the patient. In contrast
to the young girl presented here, there were no radiologi-
cal bone abnormalities or evidence of familial transmis-
sion. So far, the oncogenic potential of the GNAS1 gene
was only described for endocrine tumors, and none out of
29 glioblastomas exhibited alterations of codons 201 and
227 of GNAS1 [9]. DNA analysis of the cerebellar astrocy-
toma in the present case did not show any mutations of
the two gsp mutation sites or within the coding region
between exon 2 and exon 13 of GNAS1 apart from the
described intronic germline polymorphism. Endocrine tu-
mors, such as growth hormone producing pituitary tu-
mors or ovarian and testicular Leydig cell tumors, are
associated with activation of the Gs protein, whereas
AHO is combined with a reduced Gs protein activity.
This functional discrepancy and the lack of mutations at
the gsp mutations sites of GNAS1 in the cerebellar astro-
cytoma support the notion that the GS· protein is rather
not involved in the tumorigenesis of pediatric gliomas.
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